See all our blog articles & latest research about hereditary cancer
Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formation of cancer cells which grow uncontrollably and f..
In May 2024, the American Society of Clinical Oncology (ASCO) published new guidelines for germline genetic testing in patients with cancer (1). Introduction to hereditary cancer and germline ..
A recent study highlights promising outcomes for BRCA variant carriers with breast cancer undergoing breast-conserving therapy. Analyzing 172 women, the research found that despite higher risks of ip..
Cancer can sometimes run in families; in fact, it is estimated that 5-10% of all cancer cases are inherited. This includes up to 10% of breast cancers and up to 25% of ovarian cancers. The characteri..
Overview In January 2024, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) published new recommendations for hereditary breast cancer genetic testing (1)..
Cancer is a group of genetic diseases that can develop almost anywhere in the body. Many people in the world are affected by cancer every year. Following our video that explains the basics of cancer,..
Cancer is a complex genetic disease that affects millions of people in the world. It is one of the leading causes of death worldwide, with about ten million deaths in 2020 (1). Understanding the caus..
A recent paper published in Nature Medicine (1) aimed to identify genes and genomic biomarkers which can better predict outcomes and personalized therapy for cancer patients by integrating genetic wi..
Liquid biopsy is a novel, non-invasive blood test that enables healthcare providers to discover a range of information about a tumor, such as early cancer detection, genetic alterations that lead to ..
A recent article published by our team in the International Journal of Molecular Sciences [1], aimed to evaluate the prevalence, prognostic and predictive values of gene mutations in patients with pr..
Medicover Genetics’ technology transfer platform offers comprehensive testing in a single sequencing run, making it a unique and efficient solution for laboratories of any size. With our Technology Transfer platform, laboratories can perform multi-disciplinary genetic tests such as NIPT, cardiac, hereditary cancer, carrier screening, and metabolic testing all in a single sequencing run. This improves turnaround time and reduces operational costs while ensuring high-quality results with no compromise on accuracy. Our comprehensive testing approach is ideal for laboratories looking to provide a wide range of genetic tests to their healthcare associates and patients.
Our Technology Transfer platform workflow is designed to minimize the risk of errors, reduce hands-on processing and increase the accuracy of test results, providing confidence to patients and physicians in making informed decisions with our user-friendly protocols. The implementation of these protocols ensures that laboratory personnel are trained to follow standardized procedures, reducing the likelihood of human error, and increasing the quality of results.
Medicover Genetics’ versatile Technology Transfer platform can be integrated in a single workflow, offering a multidisciplinary portfolio of genetic tests. VERACITY, VERACITY High Content (HC) and TarCET IVD kits are CE-marked and include user friendly color identification formatting. VERACITY and VERACITY HC kits contain 96 reactions and TarCET IVD kits contain 16 reactions.
We work closely with laboratories to meet their unique needs and goals. We understand that every laboratory is different, and we tailor our approach to accommodate the specific requirements of each partner. In collaboration with our partners, we design a seamless integrated process, from initial setup to ongoing support and maintenance. Our experienced team provides technical, commercial, and marketing assistance to ensure a successful partnership and optimal performance. We aim to build long-lasting partnerships that are mutually beneficial.
